anxiety disorders
Conditions
Interventions
Experimental group: 60 participants of both sexes will be selected, in which they present an anxiety index through the DASS21 above 8 points for anxiety and 10 points for the general index. These part
Sponsors
Universidade de Franca
Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)
Eligibility
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: Participants must be over 18 years old and less than 60 years old; They must reside in the city for at least 12 months; Present internet access with a valid email address or a valid WhatsApp number. Present a score above 8 on the Depression, Anxiety and Stress Scale anxiety test and above 10 on the general test.
Exclusion criteria
Exclusion criteria: Age within 18 years or above 60 years; Not residing in Franca/SP; Use benzodiazepines in the last 30 days; Use non-selective monoamine reuptake inhibitors (Imipramine, Clomipramine, Amitriptyline, Nortriptyline) , Serotonin Reuptake Inhibitors and ALPHA-2 (alfa2) Antagonists (Nefazodone, Trazodone), Selective Dopamine Reuptake Inhibitors (Bupropion), ALPHA-2 (alfa2) Antagonists (Mirtazapine), Monoamine Oxidase Inhibitors (Tranylcypromine, Moclobemide); Not having high blood pressure. Not being pregnant.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| It is expected to find the anxiolytic potential of the aromatic blend developed for this purpose, from the identification of the DASS21 scale (Depression, Anxiety and Stress Scale), compared to the beginning. We also want to find a difference between the intervention group and the placebo control. | — |
Secondary
| Measure | Time frame |
|---|---|
| It is expected to find the potential on sleep quality through the aromatic blend developed for this purpose compared to the beginning. It is also desired to find a difference between the intervention group and placebo control. | — |
Countries
Brazil
Contacts
Public ContactSilvio Junior
Universidade de Franca
Outcome results
None listed